<DOC>
	<DOCNO>NCT00005059</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness carboplatin paclitaxel treat patient metastatic recurrent unresectable non-small cell lung cancer .</brief_summary>
	<brief_title>Carboplatin Paclitaxel Treating Older Patients With Metastatic Recurrent Unresectable Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate carboplatin paclitaxel elderly patient metastatic recurrent unresectable non-small cell lung cancer . II . Determine toxicity regimen patient . III . Determine hypothesize lack social support impact recruitment elderly patient clinical trial . IV . Determine previously validate tool functional status elderly predicts treatment relate toxicity superior predict ECOG performance status patient population .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer Stage IV disease OR Recurrent unresectable disease No conventional curative significant palliative therapy available Measurable disease At least one lesion minimum one dimension diameter least 20 mm No symptomatic and/or untreated CNS metastases PATIENT CHARACTERISTICS : Age : 65 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : AST great 3 time upper limit normal Renal : Creatinine clearance least 40 mL/min Other : No uncontrolled infection No uncontrolled seizure disorder No uncontrolled diabetes mellitus No malignancy within past 3 year except adequately treat basal squamous cell skin cancer noninvasive carcinoma PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic immunotherapy recurrent metastatic disease No concurrent biologic therapy Chemotherapy : No prior chemotherapy recurrent metastatic disease except radiosensitizer No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy recurrent metastatic disease except adjuvant therapy At least 4 week since prior radiotherapy great 25 % bone marrow No concurrent radiotherapy except CNS therapy Surgery : See Disease Characteristics At least 3 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>